Original Literature | Model OverView |
---|---|
Publication
Title
IRAK1: a critical signaling mediator of innate immunity.
Affiliation
Immunology, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.,San Diego, CA 92121, USA.
Abstract
The innate immune system is equipped with sensitive and efficient machineries toprovide an immediate, first line defense against infections. Toll-like receptors(TLRs) detect pathogens and the IL-1 receptor (IL-1R) family enables cells toquickly respond to inflammatory cytokines by mounting an efficient protectiveresponse. Interleukin-1 receptor activated kinases (IRAKs) are key mediators inthe signaling pathways of TLRs/IL-1Rs. By means of their kinase and adaptorfunctions, IRAKs initiate a cascade of signaling events eventually leading toinduction of inflammatory target gene expression. Due to this pivotal role, IRAKfunction is also highly regulated via multiple mechanisms. In this review, wefocus on IRAK1, the earliest known and yet the most interesting member of thisfamily. An overview on its structure, function and biology is given, withemphasis on the different novel mechanisms that regulate IRAK1 function. We alsohighlight several unresolved questions in this field and evaluate the potentialof IRAK1 as a target for therapeutic intervention.
PMID
17890055
|
Entity
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m41
10
infinite
0
TRANSPATH | MO000000058 |
--
MAPKs{active}
--
MO000000077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m69
10
infinite
0
TRANSPATH | MO000000077 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
Tollip
--
MO000019406
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3973
10
infinite
0
InterPro | IPR000008 |
TRANSPATH | MO000019406 |
--
IRAK-4
--
MO000039077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17258
10
infinite
0
TRANSPATH | MO000039077 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
TLR9:Ligand
--
e10
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m10
0
infinite
0
--
IL-33R
--
e11
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m11
0
infinite
0
--
IRAK1
--
e12
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m12
0
infinite
0
--
IFN-alpha
--
e13
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m13
0
infinite
0
--
IFN_alpha
--
e14
cso30:c:mRNA
cso30:i:CC_Cytosol
--
csml-variable:Double
m14
0
infinite
0
--
Activating Ligand
--
e15
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m15
0
infinite
0
--
TLR7:Ligand
--
e16
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m16
0
infinite
0
--
IL-12
--
e17
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m17
0
infinite
0
--
IRAK1:Tollip
--
e18
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m18
0
infinite
0
--
TLR
--
e19
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR:Ligand
--
e20
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m20
0
infinite
0
--
IL-1:IL-1R:MyD88
--
e21
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m21
0
infinite
0
--
TLR:Ligand:MyD88
--
e22
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m22
0
infinite
0
--
IL-1:IL-1R:MyD88:IRAK1:Tollip
--
e23
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m23
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1:Tollip
--
e24
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m24
0
infinite
0
--
IL-1:IL-1R:MyD88:IRAK1:Tollip:IRAK-4
--
e25
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m25
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1:Tollip:IRAK-4
--
e26
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m26
0
infinite
0
--
IL-1:IL-1R:MyD88:IRAK1:Tollip:IRAK-4:TRAF6
--
e27
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m27
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1:Tollip:IRAK-4:TRAF6
--
e28
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m28
0
infinite
0
--
IL-1:IL-1R:MyD88:IRAK1{p}:Tollip:IRAK-4:TRAF6
--
e29
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1{p}:Tollip:IRAK-4:TRAF6
--
e30
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m30
0
infinite
0
--
IL-1:IL-1R:MyD88:IRAK1{p}{p}:Tollip:IRAK-4:TRAF6
--
e31
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m31
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1{p}{p}:Tollip:IRAK-4:TRAF6
--
e32
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m32
0
infinite
0
--
IRAK1{p}:TRAF6
--
e33
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m33
0
infinite
0
--
IL-1:IL-1R:MyD88::Tollip:IRAK-4
--
e34
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m34
0
infinite
0
--
TLR:Ligand:MyD88:IRAK4:Tollip
--
e35
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m35
0
infinite
0
--
IRAK1:TRAF6:IRAK-4:Pellino1
--
e36
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m36
0
infinite
0
--
IRAK1:TRAF6:IRAK-4:Pellino1:TAK1
--
e37
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m37
0
infinite
0
--
Uev1A
--
e38
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m38
0
infinite
0
--
IRAK1:TRAF6:Pellino1:IRAK-4:TAK1:TAB1:TAB2
--
e39
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
NF-kappaB{active}
--
e41
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m42
10
infinite
0
TRANSPATH | MO000000058 |
--
Proinflammatory cytokines
--
e42
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m43
0
infinite
0
--
IRAK1{sumo}
--
e43
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m44
0
infinite
0
--
IRAK1
--
e44
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m45
0
infinite
0
--
IL10gene
--
e46
cso30:c:Dna
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m47
0
infinite
0
--
IRAK1:IL-10promoter
--
e47
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m48
0
infinite
0
--
IRF7
--
e48
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m49
0
infinite
0
--
TLR9:Ligand:MyD88:IRAK1:TRAF6:IRF7{p}
--
e49
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m63
0
infinite
0
--
IL-1R
--
e5
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
IL-1:IL-1R
--
e6
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
TLR7:Ligand:MyD88
--
e63
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m64
0
infinite
0
--
IRF7
--
e64
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m65
0
infinite
0
--
degradants
--
e66
cso30:c:EntityBiological
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m67
0
infinite
0
--
LPS:TLR4
--
e67
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m68
0
infinite
0
--
PKC specific inhibitors
--
e68
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m70
0
infinite
0
--
IRAK1c
--
e69
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m71
0
infinite
0
--
IL-33
--
e7
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m7
0
infinite
0
--
IRAK1:IRAK1c
--
e70
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m72
0
infinite
0
--
IRAK1:IRAK1c:Tollip
--
e71
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m73
0
infinite
0
--
csml-variable:Double
m74
0
infinite
0
--
IRAK2:IRAK1c
--
e73
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m75
0
infinite
0
--
IRAK1c:IRAK2:Tollip
--
e74
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m76
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1c:IRAK2:Tollip
--
e75
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m77
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1c:IRAK2:Tollip:TRAF6
--
e76
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m78
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1c:IRAK1:Tollip
--
e77
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m79
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1c:IRAK1:Tollip:TRAF6
--
e78
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m80
0
infinite
0
--
GMCSF
--
e79
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m81
0
infinite
0
--
IL-33:IL-33R
--
e8
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m8
0
infinite
0
--
GMCSF-R
--
e80
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m82
0
infinite
0
--
GMCSF:GMCSF-R
--
e81
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m83
0
infinite
0
--
IFN-gammaR
--
e82
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m84
0
infinite
0
--
GMCSF:GMCSF-R
--
e83
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m85
0
infinite
0
--
TLR:Ligand:MyD88:IRAK1:Tollip:IRAK-4:TRAF6:BCL-10
--
e84
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m86
0
infinite
0
--
TLR9:Ligand:MyD88
--
e85
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m87
0
infinite
0
--
TLR9:Ligand:MyD88:IRAK1
--
e86
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m88
0
infinite
0
--
TLR9:Ligand:MyD88:IRAK1:TRAF6
--
e87
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m89
0
infinite
0
--
TLR9:Ligand:MyD88:IRAK1:TRAF6:IRF7
--
e88
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m90
0
infinite
0
--
TLR7:Ligand:MyD88:IRAK1
--
e89
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m91
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
TLR7:Ligand:MyD88:IRAK1:TRAF6
--
e90
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m92
0
infinite
0
--
TLR7:Ligand:MyD88:IRAK1:TRAF6:IRF7
--
e91
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m93
0
infinite
0
--
TLR7:Ligand:MyD88:IRAK1:TRAF6:IRF7{P}
--
e92
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m94
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m185*m5*0.1
nodelay
--
0
PMID: 17890055 IL-1 induces a wide variety of inflammatory mediators including IL-6 and tumor necrosis factor (TNF) alpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c30 : 1
stoichiometry:c31 : 1
m15*m19828*0.1
nodelay
--
0
PMID: 17890055,15767370 IFN-alpha production induced by intravenous injection of TLR7 agonists is completely blocked in IRAK1-deficient mice but IL-12 production remains normal PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
p11
p11
cso30:i:ME_Translation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c34 : 1
stoichiometry:c36 : 1
stoichiometry:c35 : 1
m12*m17*m10*0.1
nodelay
--
0
PMID: 17890055,12626533 However, another study using splenocytes from IRAK1-deficient animals reported a significant reduction in TNF-alpha and IL-12 upon TLR9 activation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m14*m12*m10*0.1
nodelay
--
0
PMID: 17890055 Together, these results suggest that IRAK1 plays a specific and essential role in IFN-alpha induction downstream of TLR7 and TLR9
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c42 : 1
stoichiometry:c43 : 1
m12*m3973*0.1
nodelay
--
0
PMID: 17890055,10854325,16428431 Prior to receptor activation, IRAK1 is associated with Tollip in the cytosol
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c45 : 1
stoichiometry:c46 : 1
m19*m15*0.1
nodelay
--
0
PMID: 17890055 Upon ligand binding to TLR/IL-1R, myeloid differentiation factor 88 (MyD88) is rapidly recruited to the receptor via interaction of Toll/IL-1R (TIR) domains which are present in both MyD88 and TLR/IL-1R.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m6*m1572*0.1
nodelay
--
0
PMID: 17890055 Upon ligand binding to TLR/IL-1R, myeloid differentiation factor 88 (MyD88) is rapidly recruited to the receptor via interaction of Toll/IL-1R (TIR) domains which are present in both MyD88 and TLR/IL-1R.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
stoichiometry:c52 : 1
m1572*m20*0.1
nodelay
--
0
PMID: 17890055 Upon ligand binding to TLR/IL-1R, myeloid differentiation factor 88 (MyD88) is rapidly recruited to the receptor via interaction of Toll/IL-1R (TIR) domains which are present in both MyD88 and TLR/IL-1R.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c54 : 1
stoichiometry:c55 : 1
m18*m21*0.1
nodelay
--
0
PMID: 17890055,9430229,17276401 IRAK1 is also recruited to the receptor complex through a death domain interaction with MyD88
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m18*m22*0.1
nodelay
--
0
PMID: 17890055,9430229,17276401 IRAK1 is also recruited to the receptor complex through a death domain interaction with MyD88
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c60 : 1
stoichiometry:c61 : 1
m23*m17258*0.1
nodelay
--
0
PMID: 17890055,11960013 ,12538665 Binding to MyD88 brings IRAK1 and IRAK4 together at the receptor complex and facilitates the phosphorylation of IRAK1 by IRAK4 at Thr-209 and Thr-387
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c9 : 1
stoichiometry:c8 : 1
m93309*m6*0.1
nodelay
--
0
PMID: 17890055 IL-1 induces a wide variety of inflammatory mediators including IL-6 and tumor necrosis factor (TNF) alpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
m17258*m24*0.1
nodelay
--
0
PMID: 17890055,11960013 ,12538665 Binding to MyD88 brings IRAK1 and IRAK4 together at the receptor complex and facilitates the phosphorylation of IRAK1 by IRAK4 at Thr-209 and Thr-387
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c65 : 1
stoichiometry:c67 : 1
m183*m25*0.1
nodelay
--
0
PMID: 17890055,11287640 IRAK1 also binds tumor necrosis factor receptor-associated factor 6 (TRAF6) through multiple regions including the death domain, the undefined domain and the C-terminal C1 domain PMID: 17890055 IRAK1 also interacts with TRAF6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
m183*m26*0.1
nodelay
--
0
PMID: 17890055,11287640 IRAK1 also binds tumor necrosis factor receptor-associated factor 6 (TRAF6) through multiple regions including the death domain, the undefined domain and the C-terminal C1 domain PMID: 17890055 IRAK1 also interacts with TRAF6
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c72 : 1
m27*0.1
nodelay
--
0
PMID: 17890055,11960013 ,12538665 Binding to MyD88 brings IRAK1 and IRAK4 together at the receptor complex and facilitates the phosphorylation of IRAK1 by IRAK4 at Thr-209 and Thr-387
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
m28*0.1
nodelay
--
0
PMID: 17890055,11960013 ,12538665 Binding to MyD88 brings IRAK1 and IRAK4 together at the receptor complex and facilitates the phosphorylation of IRAK1 by IRAK4 at Thr-209 and Thr-387
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c76 : 1
m29*0.1
nodelay
--
0
PMID: 17890055,8599092,17141195 This results in the activation of IRAK1 kinase activity and thus the formation of hyper-phosphorylated IRAK1 via auto-phosphorylation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c78 : 1
m30*0.1
nodelay
--
0
PMID: 17890055,8599092,17141195 This results in the activation of IRAK1 kinase activity and thus the formation of hyper-phosphorylated IRAK1 via auto-phosphorylation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m31*0.1
nodelay
--
0
PMID: 17890055,9430229 Since MyD88 and Tollip only bind to non-phosphorylated IRAK1, hyper-phosphorylated IRAK1 is then released from MyD88 and the receptor complex, a key step in this signaling cascade PMID: 17890055 Hyper-phosphorylated IRAK1 then disengages from MyD88 and Tollip, and forms a cytosolic IRAK1-TRAF6 complex
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c83 : 1
stoichiometry:c84 : 1
m32*0.1
nodelay
--
0
PMID: 17890055,9430229 Since MyD88 and Tollip only bind to non-phosphorylated IRAK1, hyper-phosphorylated IRAK1 is then released from MyD88 and the receptor complex, a key step in this signaling cascade PMID: 17890055 Hyper-phosphorylated IRAK1 then disengages from MyD88 and Tollip, and forms a cytosolic IRAK1-TRAF6 complex
p29
p29
cso30:i:ME_Binding
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c87 : 1
stoichiometry:c88 : 1
m33*m19287*m17258*0.1
nodelay
--
0
PMID: 17890055,12496252 An intermediate cytosolic signaling complex composed of Pellino1, IRAK1, IRAK4 and TRAF6 may be formed prior to the interaction of TRAF6 with the downstream signaling molecule TGF-beta activated kinase-1 (TAK1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c6 : 1
stoichiometry:c5 : 1
m93248*m6*0.1
nodelay
--
0
PMID: 17890055 IL-1 induces a wide variety of inflammatory mediators including IL-6 and tumor necrosis factor (TNF) alpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c90 : 1
stoichiometry:c91 : 1
m36*m1573*0.1
nodelay
--
0
PMID: 17890055,12496252 An intermediate cytosolic signaling complex composed of Pellino1, IRAK1, IRAK4 and TRAF6 may be formed prior to the interaction of TRAF6 with the downstream signaling molecule TGF-beta activated kinase-1 (TAK1)
p31
p31
cso30:i:ME_Binding
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c92 : 1
stoichiometry:c93 : 1
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c97 : 1
m37*m6433*m1583*m6443*m38*0.1
nodelay
--
0
PMID: 17890055,10882101,12242293,11057907 Cytosolic TRAF6 interacting with TAK1 eventually forms a macromolecular complex with ubiquitin conjugating enzymes Ubc13 and Uev1A, and TAK1 binding proteins TAB1 and TAB2
p32
p32
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c98 : 1
stoichiometry:c99 : 1
stoichiometry:c100 : 1
m39*m40*0.1
nodelay
--
0
PMID: 17890055,11518704,10465784 This leads to TAK1 activation, which in turn activates NF-¦ÊB and MAPK pathways
p32
p33
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c103 : 1
stoichiometry:c102 : 1
m41*m39*0.1
nodelay
--
0
PMID: 17890055,11518704,10465784 This leads to TAK1 activation, which in turn activates NF-¦ÊB and MAPK pathways
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c105 : 1
m69*0.1
nodelay
--
0
PMID: 17890055,11518704,10465784 This leads to TAK1 activation, which in turn activates NF-¦ÊB and MAPK pathways
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
m42*0.1
nodelay
--
0
PMID: 17890055,11518704,10465784 This leads to TAK1 activation, which in turn activates NF-¦ÊB and MAPK pathways
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
m44*0.1
nodelay
--
0
PMID: 17890055,10899313,15896328 IRAK1 has been reported to translocate to the nucleus upon IL-1 stimulation PMID: 17890055,16690127 A recent study also indicated that IRAK1 undergoes sumoylation followed by nuclear translocation in monocytes stimulated with TLR ligands
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c109 : 1
stoichiometry:c110 : 1
m33*0.1
nodelay
--
0
PMID: 17890055,16690127 A recent study also indicated that IRAK1 undergoes sumoylation followed by nuclear translocation in monocytes stimulated with TLR ligands
p38
p38
cso30:i:ME_Phosphorylation
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c114 : 1
stoichiometry:c115 : 1
m45*m1360*0.1
nodelay
--
0
PMID: 17890055,15465816 Within the nucleus, IRAK1 has been reported to phosphorylate transcription factor Stat3 and bind directly to the IL-10 gene promoter for IL-10 expression
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c120 : 1
m48*0.1
nodelay
--
0
PMID: 17890055,15465816 Within the nucleus, IRAK1 has been reported to phosphorylate transcription factor Stat3 and bind directly to the IL-10 gene promoter for IL-10 expression
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m7*m11*0.1
nodelay
--
0
PMID: 17890055,16286016 IL-33-treatment of Th2 T cells induces IL-5 and IL-13 production
p40
p40
cso30:i:ME_DNABinding
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c116 : 1
stoichiometry:c117 : 1
stoichiometry:c118 : 1
m45*m47*0.1
nodelay
--
0
PMID: 17890055,15465816 Within the nucleus, IRAK1 has been reported to phosphorylate transcription factor Stat3 and bind directly to the IL-10 gene promoter for IL-10 expression
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c126 : 1
m65*0.1
nodelay
--
0
PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c122 : 1
m90*0.1
nodelay
--
0
PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c127 : 1
stoichiometry:c124 : 1
m63*0.1
nodelay
--
0
PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c128 : 1
stoichiometry:c129 : 1
stoichiometry:c130 : 1
m1572*m16*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-greek small letter alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7)
p45
p45
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c137 : 1
stoichiometry:c138 : 1
stoichiometry:c166 : 1
stoichiometry:c170 : 1
stoichiometry:c132 : 1
stoichiometry:c133 : 1
m33*m68*0.1
nodelay
--
0
PMID: 17890055,9261174 The loss of IRAK1 protein is due to proteasome-mediated degradation as demonstrated by studies using proteasome inhibitors PMID: 17890055,11937546 TLR4 activation can also trigger rapid IRAK1 degradation that can be blocked by protein kinase C (PKC) specific inhibitors PMID: 17890055,12032143 Interestingly, degradation of IRAK1 in LPS-tolerant THP-1 cells can be prevented by pretreatment with GM-CSF and IFN-¦Ã
p46
p46
cso30:i:ME_Binding
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c135 : 1
stoichiometry:c136 : 1
m3961*m155666*0.1
nodelay
--
0
PMID: 17890055,11937546 TLR4 activation can also trigger rapid IRAK1 degradation that can be blocked by protein kinase C (PKC) specific inhibitors
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c139 : 1
stoichiometry:c140 : 1
stoichiometry:c141 : 1
m12*m71*0.1
nodelay
--
0
PMID: 17890055 In resting cells, IRAK1c dimerizes with IRAK1 or IRAK2 and associates with Tollip.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c143 : 1
stoichiometry:c144 : 1
m72*m3973*0.1
nodelay
--
0
PMID: 17890055 n resting cells, IRAK1c dimerizes with IRAK1 or IRAK2 and associates with Tollip.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c146 : 1
stoichiometry:c147 : 1
m71*m74*0.1
nodelay
--
0
PMID: 17890055 In resting cells, IRAK1c dimerizes with IRAK1 or IRAK2 and associates with Tollip.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m93275*m8*0.1
nodelay
--
0
PMID: 17890055,16286016 IL-33-treatment of Th2 T cells induces IL-5 and IL-13 production
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c149 : 1
stoichiometry:c150 : 1
m75*m3973*0.1
nodelay
--
0
PMID: 17890055 In resting cells, IRAK1c dimerizes with IRAK1 or IRAK2 and associates with Tollip.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c151 : 1
stoichiometry:c152 : 1
stoichiometry:c153 : 1
m76*m22*0.1
nodelay
--
0
PMID: 17890055 Upon TLR activation, IRAK1c is recruited to the receptor complex and interacts with MyD88 and TRAF6 in a manner similar to IRAK1 and IRAK1-kinase dead mutant.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c154 : 1
stoichiometry:c155 : 1
stoichiometry:c156 : 1
m183*m77*0.1
nodelay
--
0
PMID: 17890055 Upon TLR activation, IRAK1c is recruited to the receptor complex and interacts with MyD88 and TRAF6 in a manner similar to IRAK1 and IRAK1-kinase dead mutant.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c157 : 1
stoichiometry:c158 : 1
stoichiometry:c159 : 1
m22*m73*0.1
nodelay
--
0
PMID: 17890055 Upon TLR activation, IRAK1c is recruited to the receptor complex and interacts with MyD88 and TRAF6 in a manner similar to IRAK1 and IRAK1-kinase dead mutant.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c160 : 1
stoichiometry:c161 : 1
stoichiometry:c162 : 1
m79*m183*0.1
nodelay
--
0
PMID: 17890055 Upon TLR activation, IRAK1c is recruited to the receptor complex and interacts with MyD88 and TRAF6 in a manner similar to IRAK1 and IRAK1-kinase dead mutant.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c163 : 1
stoichiometry:c164 : 1
stoichiometry:c165 : 1
m81*m82*m83*0.1
nodelay
--
0
PMID: 17890055,12032143 Interestingly, degradation of IRAK1 in LPS-tolerant THP-1 cells can be prevented by pretreatment with GM-CSF and IFN-¦Ã
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c167 : 1
stoichiometry:c168 : 1
stoichiometry:c169 : 1
m1639*m84*0.1
nodelay
--
0
PMID: 17890055,12032143 Interestingly, degradation of IRAK1 in LPS-tolerant THP-1 cells can be prevented by pretreatment with GM-CSF and IFN-¦Ã
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c171 : 1
stoichiometry:c172 : 1
stoichiometry:c173 : 1
m28*m21910*0.1
nodelay
--
0
PMID: 17890055,16831874 IRAK1 also acts as an upstream adaptor by recruiting B-cell CLL/lymphoma 10 (BCL10) to the TLR signaling complex
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c174 : 1
stoichiometry:c175 : 1
stoichiometry:c199 : 1
m1572*m10*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c176 : 1
stoichiometry:c177 : 1
stoichiometry:c178 : 1
m12*m87*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-greek small letter alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m93493*m8*0.1
nodelay
--
0
PMID: 17890055,16286016 IL-33-treatment of Th2 T cells induces IL-5 and IL-13 production
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c179 : 1
stoichiometry:c180 : 1
stoichiometry:c181 : 1
m88*m183*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c182 : 1
stoichiometry:c183 : 1
stoichiometry:c184 : 1
m89*m49*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c185 : 1
stoichiometry:c186 : 1
stoichiometry:c187 : 1
m64*m12*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-greek small letter alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c188 : 1
stoichiometry:c189 : 1
stoichiometry:c190 : 1
m91*m183*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-greek small letter alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c194 : 1
stoichiometry:c195 : 1
m93*0.1
nodelay
--
0
PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c191 : 1
stoichiometry:c192 : 1
stoichiometry:c193 : 1
m92*m49*0.1
nodelay
--
0
PMID: 17890055 Further biochemical studies showed that IFN-greek small letter alpha induction requires the formation of a signaling complex consisting of IRAK1, MyD88, TRAF6 and IFN-regulatory factor 7 (IRF7) PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c197 : 1
stoichiometry:c198 : 1
m94*0.1
nodelay
--
0
PMID: 17890055,15767370 IRAK1 directly binds IRF7 and its kinase activity is critical for the phosphorylation and activation of IRF7, a requirement for IRF7 nuclear translocation and INF-alpha production PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c25 : 1
stoichiometry:c21 : 1
m14*m12*m16*0.1
nodelay
--
0
PMID: 17890055,15767370 IFN-alpha production induced by intravenous injection of TLR7 agonists is completely blocked in IRAK1-deficient mice but IL-12 production remains normal PMID: 17890055,15767370 IRAK1 deficiency in plasmacytoid dendritic cells abrogates IFN-alpha production without affecting the production of other inflammatory cytokines such as IL-6 and TNF-alpha
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m15*m19940*0.1
nodelay
--
0
PMID: 17890055,15767370 IFN-alpha production induced by intravenous injection of TLR7 agonists is completely blocked in IRAK1-deficient mice but IL-12 production remains normal PMID: 17890055 As previously mentioned, IRAK1 plays a key role in IFN-alpha gene expression upon TLR7 or TLR9 activation.
p9
p9
cso30:i:ME_Translation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c26 : 1
stoichiometry:c27 : 1
stoichiometry:c33 : 1
stoichiometry:c28 : 1
m12*m93309*m10*0.1
nodelay
--
0
PMID: 17890055,12626533 However, another study using splenocytes from IRAK1-deficient animals reported a significant reduction in TNF-alpha and IL-12 upon TLR9 activation
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--